Figure 3.

miR-29b mediates AngII-induced muscle atrophy by targeting Yin Yang 1 (YY1)

(A) TargetScan and luciferase assay analysis of the direct interact with YY1 and miR-29b. n = 6 per group. (B) Quantitative real-time PCR analysis of Yy1 expression in C2C12 myotubes transfected with miR-29b mimic. n = 6 per group. (C) Quantitative real-time PCR analysis of Yy1 expression in C2C12 myotubes transfected with miR-29b inhibitor. n = 6 per group. (D) Western blot analysis of YY1 expression in C2C12 myotubes transfected with miR-29b mimic. n = 3 per group. (E) Western blot analysis of YY1 expression in C2C12 myotubes transfected with miR-29b inhibitor. n = 3 per group. (F) Western blot analysis of YY1 expression in C2C12 myotubes treated with AngII. n = 3 per group. (G) Western blot analysis of YY1 expression in the gastrocnemius from control and AngII treated mice. n = 3 per group. (H) Immunofluorescent staining for C2C12 myotubes and quantitative real-time PCR analysis of Atrogin-1 and Murf-1 expression showed that overexpression of YY1 reduced muscle atrophy induced by AngII. n = 4 per group for staining. n = 3–4 for quantitative real-time PCR. Scale bar: 100 μm. (I) Immunofluorescent staining for C2C12 myotubes and quantitative real-time PCR analysis of Atrogin-1 and Murf-1 expression when knockdown YY1 together with miR-29b inhibition in AngII-induced muscle atrophy. n = 4 per group for staining. n = 6 for quantitative real-time PCR. Scale bar: 100 μm. Data are shown as mean ± SD. ∗p < 0.05. ∗∗p < 0.01. ns, no significance. See also Figure S3.